ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma—A Children's Oncology Group study
- James I. Geller
- , Joseph G. Pressey
- , Malcolm A. Smith
- , Rachel A. Kudgus
- , Mariana Cajaiba
- , Joel M. Reid
- , David Hall
- , Donald A. Barkauskas
- , Stephen D. Voss
- , Steve Y. Cho
- , Stacey L. Berg
- , Jeffrey S. Dome
- , Elizabeth Fox
- , Brenda J. Weigel
Research output: Contribution to journal › Article › peer-review
43
Link opens in a new tab
Scopus
citations